{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:41:36Z","timestamp":1787510496716,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd008170","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,1,11]],"date-time":"2015-01-11T00:00:00Z","timestamp":1420934400000}}],"reference-count":121,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008170.pub2","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T23:01:47Z","timestamp":1420930907000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension"],"prefix":"10.1002","author":[{"given":"Hao","family":"Xue","sequence":"first","affiliation":[{"name":"School of Pharmacy, Fudan University; Department of Pharmacology; 826 Zhangheng Road Shanghai China 201203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Fudan University; Department of Pharmacology; 826 Zhangheng Road Shanghai China 201203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Lu","family":"Tang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Fudan University; Department of Pharmacology; 826 Zhangheng Road Shanghai China 201203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu Wei","family":"Pang","sequence":"additional","affiliation":[{"name":"Karolinska Institute; Department of Epidemiology; Solnav\u00e4gen 1 Stockholm Sweden 17177"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan Mi","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Fudan University; Department of Pharmacology; 826 Zhangheng Road Shanghai China 201203"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin WK","family":"Wong","sequence":"additional","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Wright","sequence":"additional","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,11]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD008170.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","journal-title":"JAMA"},{"issue":"20","key":"10.1002\/14651858.CD008170.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","article-title":"Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"166","author":"Barzilay","year":"2006","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008170.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diacare.24.4.654","article-title":"Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"24","author":"Barzilay","year":"2001","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc07-1452","article-title":"Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"31","author":"Black","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"30A","DOI":"10.1016\/j.amjhyper.2004.03.069","article-title":"Blood pressure control by randomized drug group in ALLHAT","volume":"17","author":"Cushman","year":"2004","journal-title":"American Journal of Hypertension"},{"issue":"22","key":"10.1002\/14651858.CD008170.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"118","author":"Davis","year":"2008","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD008170.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"issue":"9 Suppl A","key":"10.1002\/14651858.CD008170.pub2-BIB0008|cit8","first-page":"350a","article-title":"Did blood pressure medication withdrawal prior to randomization influence subsequent rates of heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial?","volume":"49","author":"Grimm","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD008170.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1751-7176.2009.00149.x","article-title":"Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?","volume":"11","author":"Grimm","year":"2009","journal-title":"Journal of Clinical Hypertension"},{"issue":"22","key":"10.1002\/14651858.CD008170.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","article-title":"Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)","volume":"54","author":"Haywood","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000231662.77359.de","article-title":"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"48","author":"Leenen","year":"2006","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FPC.0b013e32832a8e81","article-title":"Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study","volume":"19","author":"Lynch","year":"2009","journal-title":"Pharmacogenetics and Genomics"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0013|cit13","first-page":"296","article-title":"Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. [Erratum appears in JAMA. 2009 Sep 9;302(10):1057-8]","volume":"299","author":"Lynch","year":"2008","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Probstfield JL Cushman WC Davis BR Pressel S Cutler JA Einhorn P Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) European Society of Cardiology, ESC Congress; 2010 Aug 28-Sep 1; Stockholm, Sweden 2010 321","DOI":"10.1016\/S0145-4145(10)79850-6"},{"issue":"8","key":"10.1002\/14651858.CD008170.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Archives of Internal Medicine"},{"issue":"13","key":"10.1002\/14651858.CD008170.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"168","author":"Wright","year":"2008","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"e34217","DOI":"10.1371\/journal.pone.0034217","article-title":"Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"9","key":"10.1002\/14651858.CD008170.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/01.STR.0000236839.69658.c5","article-title":"Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension","volume":"37","author":"Ariff","year":"2006","journal-title":"Stroke"},{"issue":"4","key":"10.1002\/14651858.CD008170.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/01.HYP.0000141273.72768.b7","article-title":"Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension","volume":"44","author":"Buus","year":"2004","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/08037050701343688","article-title":"Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade","volume":"16","author":"Buus","year":"2007","journal-title":"Blood Pressure"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1993.tb00743.x","article-title":"The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide","volume":"234","author":"Dahl\u00f6f","year":"1993","journal-title":"Journal of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008170.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200209000-00032","article-title":"Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy","volume":"20","author":"Dahl\u00f6f","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0024|cit24","first-page":"259","article-title":"Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina)","volume":"17","author":"Dalla Vestra","year":"2004","journal-title":"Diabetes Nutrition & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD008170.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(04)80049-3","article-title":"Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study","volume":"26","author":"Derosa","year":"2004","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.fjc.0000161403.91456.39","article-title":"Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension","volume":"45","author":"Derosa","year":"2005","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"277-85","DOI":"10.1111\/jcpt.12139","article-title":"Effects of enalapril\/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients","volume":"39","author":"Derosa","year":"2014","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD008170.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/hc3601.095927","article-title":"Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial","volume":"104","author":"Devereux","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clinthera.2008.03.006","article-title":"The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study","volume":"30","author":"Esnault","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0030|cit30","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD008170.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"9b","key":"10.1002\/14651858.CD008170.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"9r","DOI":"10.1016\/S0002-9149(98)00750-4","article-title":"Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial","volume":"82","author":"Estacio","year":"1998","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/clc.21994","article-title":"Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size","volume":"35","author":"Fogari","year":"2012","journal-title":"Clinical Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00004872-199816050-00017","article-title":"Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension","volume":"16","author":"Gerritsen","year":"1998","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/01.CIR.98.2.140","article-title":"Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension","volume":"98","author":"Gottdiener","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archinternmed.2011.1391","article-title":"Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial","volume":"172","author":"Hajjar","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jgs.12100","article-title":"Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial","volume":"61","author":"Hajjar","year":"2013","journal-title":"Journal of the American Geriatrics Society"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00315487","article-title":"A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia","volume":"45","author":"Hauf-Zachariou","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008170.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/jch.12004","article-title":"Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen","volume":"14","author":"Hayoz","year":"2012","journal-title":"Journal of Clinical Hypertension"},{"issue":"9","key":"10.1002\/14651858.CD008170.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0895-7061(96)00176-8","article-title":"Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to beta-blockade","volume":"9","author":"Himmelmann","year":"1996","journal-title":"American Journal of Hypertension"},{"issue":"8","key":"10.1002\/14651858.CD008170.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/HJH.0b013e328304b072","article-title":"Effect of antihypertensive treatment on retinal microvascular changes in hypertension","volume":"26","author":"Hughes","year":"2008","journal-title":"Journal of Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD008170.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008170.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"7 Pt 1","key":"10.1002\/14651858.CD008170.pub2-BIB0044|cit44","first-page":"705","article-title":"The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group","volume":"10","author":"Dahl\u00f6f","year":"1997","journal-title":"American Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.32.6.989","article-title":"Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension","volume":"32","author":"Dahl\u00f6f","year":"1998","journal-title":"Hypertension"},{"issue":"9311","key":"10.1002\/14651858.CD008170.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-139-3-200308050-00006","article-title":"Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial","volume":"139","author":"Devereux","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jacc.2005.05.060","article-title":"The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study","volume":"46","author":"Fossum","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/01.HYP.0000179604.42845.8d","article-title":"Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy","volume":"46","author":"Franklin","year":"2005","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008170.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/08037050903047202","article-title":"Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study)","volume":"18","author":"Gerdts","year":"2009","journal-title":"Blood Pressure"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2003.11.029","article-title":"Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study","volume":"43","author":"Julius","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD008170.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/01.HYP.0000151324.05355.1c","article-title":"Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study","volume":"45","author":"Kizer","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1524-6175.2005.04254.x","article-title":"The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study","volume":"7","author":"Kjeldsen","year":"2005","journal-title":"Journal of Clinical Hypertension"},{"issue":"9311","key":"10.1002\/14651858.CD008170.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0057|cit55","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jelectrocard.2009.06.020","article-title":"Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients","volume":"42","author":"Okin","year":"2009","journal-title":"Journal of Electrocardiology"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0055|cit56","first-page":"243","article-title":"Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy","volume":"6","author":"Okin","year":"2013","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"issue":"7","key":"10.1002\/14651858.CD008170.pub2-BIB0056|cit57","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ajh.2010.65","article-title":"Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients","volume":"23","author":"Okin","year":"2010","journal-title":"American Journal of Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/HJH.0b013e32831daf96","article-title":"Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study","volume":"27","author":"Olsen","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD008170.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/HYPERTENSIONAHA.107.105296","article-title":"Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study","volume":"51","author":"Os","year":"2008","journal-title":"Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD008170.pub2-BIB0061|cit60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0002-9149(02)02777-7","article-title":"Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)","volume":"90","author":"Malmqvist","year":"2002","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0060|cit61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00005344-200312000-00005","article-title":"Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)","volume":"42","author":"Malmqvist","year":"2003","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2796.2007.01775.x","article-title":"Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study","volume":"261","author":"Mortsell","year":"2007","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2796.1998.00319.x","article-title":"Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group","volume":"244","author":"Ostman","year":"1998","journal-title":"Journal of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008170.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11315250-000000000-00000","article-title":"One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study","volume":"29","author":"Parrinello","year":"2009","journal-title":"Clinical Drug Investigation"},{"issue":"8","key":"10.1002\/14651858.CD008170.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/00365519709105228","article-title":"A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years","volume":"57","author":"Pedersen","year":"1997","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0066|cit66","first-page":"375","article-title":"A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension","volume":"55","author":"Petersen","year":"2001","journal-title":"Clinical Nephrology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD008170.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-7061(97)00492-5","article-title":"Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy","volume":"11","author":"Roman","year":"1998","journal-title":"American Journal of Hypertension"},{"issue":"19","key":"10.1002\/14651858.CD008170.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008170.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.23.1.83","article-title":"Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension","volume":"23","author":"Schiffrin","year":"1994","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD008170.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.HYP.0000133249.28773.d7","article-title":"Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project","volume":"44","author":"Schneider","year":"2004","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.jhh.1001812","article-title":"Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial","volume":"19","author":"Schram","year":"2005","journal-title":"Journal of Human Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00044011-199816030-00007","article-title":"Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients: 1-year randomised, double-blind, parallel study vs atenolol","volume":"16","author":"Seedat","year":"1998","journal-title":"Clinical Drug Investigation"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1042\/cs0950709","article-title":"Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive type I diabetes patients with nephropathy","volume":"95","author":"S\u00f8rensen","year":"1998","journal-title":"Clinical Science"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diacare.22.3.491","article-title":"Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy","volume":"22","author":"Tarnow","year":"1999","journal-title":"Diabetes Care"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD008170.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0895-7061(99)00156-9","article-title":"Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients","volume":"12","author":"Tedesco","year":"1999","journal-title":"American Journal of Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD008170.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/01.hjh.0000125412.50839.b5","article-title":"Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial)","volume":"22","author":"Terpstra","year":"2004","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD008170.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.1993.03510060059034","article-title":"Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group","volume":"270","author":"Neaton","year":"1993","journal-title":"JAMA"},{"issue":"9426","key":"10.1002\/14651858.CD008170.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy","volume":"48","author":"Julius","year":"2006","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/080370598437394","article-title":"The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design","volume":"7","author":"Mann","year":"1998","journal-title":"Blood Pressure"},{"issue":"A","key":"10.1002\/14651858.CD008170.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"E33","DOI":"10.1097\/01.hjh.0000378299.43296.c3","article-title":"Predictors of stroke recurrence in high-risk, hypertensive patients","volume":"28","author":"Sandset","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD008170.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/01.hjh.0000249692.96488.46","article-title":"Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial","volume":"24","author":"Zanchetti","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ndt\/gfm731","article-title":"Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease","volume":"23","author":"Zeltner","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"19","key":"10.1002\/14651858.CD008170.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"13","key":"10.1002\/14651858.CD008170.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","author":"Materson","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/08037051.2011.649537","article-title":"The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium","volume":"21","author":"Okin","year":"2012","journal-title":"Blood Pressure"},{"issue":"13","key":"10.1002\/14651858.CD008170.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.280.13.1168","article-title":"Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"280","author":"Preston","year":"1998","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1002\/14651858.CD008170.pub2-BIB0089|cit89","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1002\/14651858.CD008170.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"issue":"7454","key":"10.1002\/14651858.CD008170.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"suppl 36","key":"10.1002\/14651858.CD008170.pub2-BIB0092|cit92","first-page":"S38","article-title":"Determinants of progressive renal disease in diabetes mellitus","volume":"41","author":"Aurell","year":"1992","journal-title":"Kidney Int Suppl"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","article-title":"Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project (CAPPP)","volume":"24","author":"Niskanen","year":"2001","journal-title":"Diabetes Care"},{"issue":"9502","key":"10.1002\/14651858.CD008170.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD008170.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003654.pub4","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Chen","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008170.pub2-BIB0096|cit96","first-page":"S117","article-title":"Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada - Treatment of Hypertension","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/1047-2797(93)90006-P","article-title":"Risk factors for coronary heart disease mortality among persons with diabetes","volume":"3","author":"DeStefano","year":"1993","journal-title":"Annals of Epidemiology"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/01.hjh.0000226182.60321.69","article-title":"Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review","volume":"24","author":"Duprez","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","article-title":"Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis","volume":"37","author":"Dzau","year":"2001","journal-title":"Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD008170.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"Task Force Members. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0749-3797(01)00399-3","article-title":"Elevated blood pressure among U.S. adults with diabetes, 1988-1994","volume":"22","author":"Geiss","year":"2002","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0102|cit102","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study investigators","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008170.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ecl.2004.11.008","article-title":"The prevention of type 2 diabetes mellitus","volume":"34","author":"Inzucchi","year":"2005","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"5","key":"10.1002\/14651858.CD008170.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD008170.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","article-title":"Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta regression analysis","volume":"118","author":"Kasiske","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00041552-200203000-00002","article-title":"Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease","volume":"11","author":"Kocks","year":"2002","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0108|cit108","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) . The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus","volume":"106","author":"MARVAL Study Investigators","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.23.7.888","article-title":"Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes","volume":"23","author":"Pahor","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Study Group","year":"2001","journal-title":"Lancet"},{"issue":"8901","key":"10.1002\/14651858.CD008170.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"RENAAL Study Investigators","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008170.pub2-BIB0114|cit114","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1","key":"10.1002\/14651858.CD008170.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1463-1326.2006.00688.x","article-title":"Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"10","author":"Saha","year":"2008","journal-title":"Diabetes Obesity and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD008170.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1464-5491.2004.01122.x","article-title":"Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials","volume":"21","author":"Siebenhofer","year":"2004","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008170.pub2-BIB0117|cit117","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004136.pub2","article-title":"Antihypertensive agents for preventing diabetic kidney disease","author":"Strippoli","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008170.pub2-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008170.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub4","article-title":"Beta-blockers for hypertension","author":"Wiysonge","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008170.pub2-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub2","article-title":"First-line drugs for hypertension","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7933","key":"10.1002\/14651858.CD008170.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008170.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008170.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T09:47:16Z","timestamp":1717667236000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008170.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,11]]},"references-count":121,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008170.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,11]]}}}